- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed sells remaining Diatide shares
Nycomed Amersham this month completed the divestiture of its remaining holdings in Londonderry, NH-based radiopharmaceutical firm Diatide. On June 16, Nycomed finalized the sale of a total of 1.5 million shares of Diatide common stock to a group
Nycomed Amersham this month completed the divestiture of its remaining holdings in Londonderry, NH-based radiopharmaceutical firm Diatide. On June 16, Nycomed finalized the sale of a total of 1.5 million shares of Diatide common stock to a group of private investors. The terms of the sale were not disclosed by either firm.
The two companies will continue their joint marketing efforts for AcuTect, Diatides FDA-approved acute deep vein thrombosis agent, and for NeoTect, its agent for lung cancer imaging, which is pending approval. Diatide has begun an aggressive business development program in an effort to find other marketing partners for products in its R&D pipeline, the company said. The sale of Buckinghamshire, U.K.-based Nycomeds shares brings to a close a partnership begun in 1995, when Nycomed made a $10 million equity investment in Diatide, then known as Diatech (SCAN 8/30/95).
© 1999 Miller Freeman, Inc.All rights reserved.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
